Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Lowered by Banque Pictet & Cie SA

Banque Pictet & Cie SA reduced its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 8.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,315 shares of the company's stock after selling 5,457 shares during the period. Banque Pictet & Cie SA's holdings in Vaxcyte were worth $4,856,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Creative Planning boosted its holdings in shares of Vaxcyte by 37.6% in the 3rd quarter. Creative Planning now owns 37,525 shares of the company's stock valued at $4,288,000 after buying an additional 10,245 shares during the period. Riverview Trust Co acquired a new position in shares of Vaxcyte in the 3rd quarter valued at about $27,000. Blue Trust Inc. boosted its holdings in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares during the period. Raymond James & Associates boosted its holdings in shares of Vaxcyte by 17.0% in the 3rd quarter. Raymond James & Associates now owns 81,235 shares of the company's stock valued at $9,283,000 after buying an additional 11,798 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Vaxcyte by 1.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 347,474 shares of the company's stock valued at $39,706,000 after buying an additional 3,922 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Trading Down 1.8 %

Vaxcyte stock traded down $1.53 during midday trading on Tuesday, reaching $82.47. 775,543 shares of the stock traded hands, compared to its average volume of 1,089,861. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06. The firm has a market cap of $10.28 billion, a price-to-earnings ratio of -17.93 and a beta of 0.98. The firm has a fifty day moving average price of $86.19 and a two-hundred day moving average price of $94.68.

Insiders Place Their Bets

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the business's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $86.22, for a total transaction of $689,760.00. Following the sale, the chief operating officer now owns 205,695 shares in the company, valued at $17,735,022.90. This trade represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,616 shares of company stock worth $6,095,681. 3.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

PCVX has been the subject of several research reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a "buy" rating and a $135.00 price target for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $14.00 target price on shares of Vaxcyte in a research note on Tuesday, February 11th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $127.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.